MD3435980T2 - Formulări injectabile de fosnetupitant echilibrate fiziologic - Google Patents
Formulări injectabile de fosnetupitant echilibrate fiziologicInfo
- Publication number
- MD3435980T2 MD3435980T2 MDE20190164T MDE20190164T MD3435980T2 MD 3435980 T2 MD3435980 T2 MD 3435980T2 MD E20190164 T MDE20190164 T MD E20190164T MD E20190164 T MDE20190164 T MD E20190164T MD 3435980 T2 MD3435980 T2 MD 3435980T2
- Authority
- MD
- Moldova
- Prior art keywords
- fosnetupitant
- injectable formulations
- pharmaceutically acceptable
- physiologically balanced
- optionally
- Prior art date
Links
- 239000007972 injectable composition Substances 0.000 title abstract 3
- HZIYEEMJNBKMJH-UHFFFAOYSA-N [4-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(2-methylphenyl)pyridin-2-yl]-1-methylpiperazin-1-ium-1-yl]methyl hydrogen phosphate Chemical compound C=1N=C(N2CC[N+](C)(COP(O)([O-])=O)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HZIYEEMJNBKMJH-UHFFFAOYSA-N 0.000 title abstract 2
- 229950010727 fosnetupitant Drugs 0.000 title abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- -1 e) optionally Chemical compound 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000012931 lyophilized formulation Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 abstract 1
- 229960002131 palonosetron Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Prezenta invenţie se referă la dozaje şi formulări injectabile de fosnetupitant şi săruri acceptabile farmaceutic ale acestuia, care sunt eficiente, stabile chimic şi echilibrate fiziologic pentru asigurarea siguranţei şi eficacităţii.Este descrisă o formulare injectabilă, lichidă sau liofilizată, care cuprinde:a) fosnetupitant sau o sare acceptabilă farmaceutic a acestuia;b) opţional, palonosetron sau o sare acceptabilă farmaceutic a acestuia;c) hidroxid de sodiu;d) edetat disodic;e) opţional, acid clorhidric; şif) manitol;precum şi o metodă de fabricare a formulării.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662345942P | 2016-06-06 | 2016-06-06 | |
PCT/EP2017/063268 WO2017211663A1 (en) | 2016-06-06 | 2017-06-01 | Physiologically balanced injectable formulations of fosnetupitant |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3435980T2 true MD3435980T2 (ro) | 2020-03-31 |
Family
ID=59055193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20190164T MD3435980T2 (ro) | 2016-06-06 | 2017-06-01 | Formulări injectabile de fosnetupitant echilibrate fiziologic |
Country Status (36)
Country | Link |
---|---|
US (3) | US10624911B2 (ro) |
EP (2) | EP3435980B1 (ro) |
JP (2) | JP6936817B2 (ro) |
KR (1) | KR102459416B1 (ro) |
CN (1) | CN109310627B (ro) |
AR (1) | AR108676A1 (ro) |
AU (1) | AU2017276588B2 (ro) |
BR (1) | BR112018074655B1 (ro) |
CA (1) | CA3025837C (ro) |
CL (1) | CL2018003338A1 (ro) |
CO (1) | CO2018011686A2 (ro) |
CY (1) | CY1122755T1 (ro) |
DK (1) | DK3435980T3 (ro) |
EA (1) | EA036605B1 (ro) |
EC (1) | ECSP19000169A (ro) |
ES (1) | ES2771226T3 (ro) |
HR (1) | HRP20200196T1 (ro) |
IL (1) | IL263126B (ro) |
JO (1) | JOP20170137B1 (ro) |
LT (1) | LT3435980T (ro) |
MA (1) | MA44513B1 (ro) |
MD (1) | MD3435980T2 (ro) |
MX (1) | MX2018015036A (ro) |
MY (1) | MY194081A (ro) |
PE (1) | PE20190347A1 (ro) |
PH (1) | PH12018502524A1 (ro) |
PL (1) | PL3435980T3 (ro) |
PT (1) | PT3435980T (ro) |
RS (1) | RS59852B1 (ro) |
SG (1) | SG11201809708PA (ro) |
SI (1) | SI3435980T1 (ro) |
TW (1) | TWI725191B (ro) |
UA (1) | UA122285C2 (ro) |
UY (1) | UY37273A (ro) |
WO (1) | WO2017211663A1 (ro) |
ZA (1) | ZA201807932B (ro) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11654154B2 (en) | 2019-01-29 | 2023-05-23 | Navinta Iii Inc | Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability |
WO2023182388A1 (ja) * | 2022-03-23 | 2023-09-28 | 大鵬薬品工業株式会社 | ホスネツピタント又はその医薬上許容される塩の安定化製剤およびその製造方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
EP1462450B1 (en) | 1993-12-29 | 2007-06-13 | MERCK SHARP & DOHME LTD. | Substituted morpholine derivatives and their use as therapeutic agents |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
US20060167072A1 (en) * | 2004-01-30 | 2006-07-27 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
US20100048607A1 (en) * | 2008-08-25 | 2010-02-25 | Chandrashekhar Kocherlakota | Formulations comprising palonosetron |
US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
SI2866797T1 (sl) * | 2012-07-06 | 2020-08-31 | Pharmathen S.A. | Stabilni injekcijski farmacevtski sestavek antagonista neurokinin 1 receptorja in postopek za njegovo pripravo |
-
2017
- 2017-06-01 BR BR112018074655-0A patent/BR112018074655B1/pt active IP Right Grant
- 2017-06-01 AU AU2017276588A patent/AU2017276588B2/en active Active
- 2017-06-01 UA UAA201812842A patent/UA122285C2/uk unknown
- 2017-06-01 EP EP17729822.1A patent/EP3435980B1/en active Active
- 2017-06-01 ES ES17729822T patent/ES2771226T3/es active Active
- 2017-06-01 CA CA3025837A patent/CA3025837C/en active Active
- 2017-06-01 SG SG11201809708PA patent/SG11201809708PA/en unknown
- 2017-06-01 WO PCT/EP2017/063268 patent/WO2017211663A1/en active Application Filing
- 2017-06-01 LT LTEP17729822.1T patent/LT3435980T/lt unknown
- 2017-06-01 PL PL17729822T patent/PL3435980T3/pl unknown
- 2017-06-01 JP JP2018563684A patent/JP6936817B2/ja active Active
- 2017-06-01 SI SI201730178T patent/SI3435980T1/sl unknown
- 2017-06-01 MX MX2018015036A patent/MX2018015036A/es active IP Right Grant
- 2017-06-01 MY MYPI2018001970A patent/MY194081A/en unknown
- 2017-06-01 MA MA44513A patent/MA44513B1/fr unknown
- 2017-06-01 KR KR1020187034943A patent/KR102459416B1/ko active IP Right Grant
- 2017-06-01 EP EP19200383.8A patent/EP3626231A1/en not_active Withdrawn
- 2017-06-01 CN CN201780034681.5A patent/CN109310627B/zh active Active
- 2017-06-01 EA EA201892837A patent/EA036605B1/ru unknown
- 2017-06-01 DK DK17729822.1T patent/DK3435980T3/da active
- 2017-06-01 PT PT177298221T patent/PT3435980T/pt unknown
- 2017-06-01 PE PE2018003074A patent/PE20190347A1/es unknown
- 2017-06-01 RS RS20200100A patent/RS59852B1/sr unknown
- 2017-06-01 MD MDE20190164T patent/MD3435980T2/ro unknown
- 2017-06-02 UY UY0001037273A patent/UY37273A/es active IP Right Grant
- 2017-06-02 AR ARP170101521A patent/AR108676A1/es unknown
- 2017-06-02 US US15/611,785 patent/US10624911B2/en active Active
- 2017-06-06 TW TW106118613A patent/TWI725191B/zh active
- 2017-06-06 JO JOP/2017/0137A patent/JOP20170137B1/ar active
-
2018
- 2018-11-09 CO CONC2018/0011686A patent/CO2018011686A2/es unknown
- 2018-11-19 IL IL263126A patent/IL263126B/en active IP Right Grant
- 2018-11-22 CL CL2018003338A patent/CL2018003338A1/es unknown
- 2018-11-23 ZA ZA2018/07932A patent/ZA201807932B/en unknown
- 2018-11-29 PH PH12018502524A patent/PH12018502524A1/en unknown
-
2019
- 2019-01-02 EC ECSENADI2019169A patent/ECSP19000169A/es unknown
-
2020
- 2020-02-06 HR HRP20200196TT patent/HRP20200196T1/hr unknown
- 2020-02-10 CY CY20201100123T patent/CY1122755T1/el unknown
- 2020-03-13 US US16/817,683 patent/US11529362B2/en active Active
-
2021
- 2021-08-27 JP JP2021138576A patent/JP7223084B2/ja active Active
-
2022
- 2022-11-15 US US17/986,934 patent/US20230172953A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2016000298A (es) | Pirazolopiridinas y pirazolopirimidinas | |
EA201992082A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
EA201300989A1 (ru) | Водная фармацевтическая композиция тапентадола для перорального введения | |
EA201201321A1 (ru) | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний | |
EA202090675A2 (ru) | Стабилизированные растворимые f-полипептиды rsv до слияния | |
EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
EA201890235A1 (ru) | Стабилизированные растворимые f-полипептиды rsv до слияния | |
EA201890654A1 (ru) | Терапевтические композиции для лечения вируса иммунодефицита человека | |
MD3482754T2 (ro) | Compoziții farmaceutice și utilizări direcționate spre tulburări de stocare lizozomale | |
EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
MD3416631T2 (ro) | Agenți terapeutici pentru bolile neurodegenerative | |
CY1120158T1 (el) | Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna | |
CL2017003437A1 (es) | Formulación solida oral que contiene irinotecán y método de preparación de la misma | |
MD3435980T2 (ro) | Formulări injectabile de fosnetupitant echilibrate fiziologic | |
EA202091385A3 (ru) | Лиофилизированные составы для антидота фактора ха | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
EA201890944A1 (ru) | Фармацевтические композиции нилотиниба гидрохлорида | |
EA201791525A2 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
CY1122598T1 (el) | Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης | |
EA201992389A1 (ru) | Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение | |
EA201590006A1 (ru) | Комбинация терапевтических средств для лечения инфекции, вызванной вирусом гепатита c | |
BR112018012947A2 (pt) | composições para higiene pessoal | |
EA201692196A1 (ru) | Применение 1,3-пропандисульфоновой кислоты или ее фармацевтически приемлемых солей для лечения саркоидоза | |
EA201500770A1 (ru) | Поливалентная вакцина против гриппа на основе гибридного белка |